Heart failure and cardiac hypertrophy

被引:18
|
作者
Rame J.E. [1 ]
Dries D.L. [1 ]
机构
[1] Division of Cardiology, University of California San Francsiso, San Francisco, CA 94143-0124
关键词
Heart Failure; Left Ventricular Hypertrophy; Losartan; Carvedilol; Main Drug Interaction;
D O I
10.1007/s11936-007-0024-3
中图分类号
学科分类号
摘要
Left ventricular failure is the final common pathway for a wide spectrum of myocardial insults, including systemic hypertension and myocardial infarction. Although left ventricular hypertrophy is an adaptive response to pressure and volume overload, this process becomes maladaptive if left untreated and pathologic cardiac hypertrophy then becomes an important and independent risk factor for the development of heart failure. Despite its importance, the transition from hypertrophy to heart failure in humans is poorly understood. The focus of treatment should be prevention of heart failure and other cardiovascular events, such as stroke and atrial fibrillation. When heart failure is present, treatment with medical and device therapy is then focused on improving functional capacity, increasing survival, and preventing progression to end-stage heart failure. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:289 / 301
页数:12
相关论文
共 50 条
  • [1] Mitochondria in cardiac hypertrophy and heart failure
    Rosca, Mariana G.
    Tandler, Bernard
    Hoppel, Charles L.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2013, 55 : 31 - 41
  • [2] Ferroptosis in cardiac hypertrophy and heart failure
    Zhang, Kuo
    Tian, Xin-Miao
    Li, Wei
    Hao, Li-Ying
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
  • [3] Epigenetics in Cardiac Hypertrophy and Heart Failure
    Liu, Chia-Feng
    Tang, W. H. Wilson
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (08): : 976 - 993
  • [4] Calcium channels in cardiac hypertrophy and heart failure
    Shorofsky S.R.
    William Balke C.
    Gwathmey J.K.
    Heart Failure Reviews, 1998, 2 (3) : 163 - 171
  • [5] Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
    Tran, Diem H.
    Wang, Zhao, V
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (12):
  • [6] Noncoding RNAs in Cardiac Hypertrophy and Heart Failure
    Lu, Peilei
    Ding, Fan
    Xiang, Yang Kevin
    Hao, Liying
    Zhao, Meimi
    CELLS, 2022, 11 (05)
  • [7] PROTEIN METABOLISM IN CARDIAC HYPERTROPHY + HEART FAILURE
    GUDBJARNASON, S
    TELERMAN, M
    BING, RJ
    AMERICAN JOURNAL OF PHYSIOLOGY, 1964, 206 (02): : 294 - &
  • [8] Statin therapy for cardiac hypertrophy and heart failure
    Liao, JK
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (04) : 248 - 253
  • [9] Role of MicroRNAs in Cardiac Hypertrophy and Heart Failure
    Wang, Nan
    Zhou, Zhen
    Liao, Xinghua
    Zhang, Tongcun
    IUBMB LIFE, 2009, 61 (06) : 566 - 571
  • [10] RNA methylation in cardiac hypertrophy and heart failure
    Buchholz, E.
    Berulava, T.
    Lbik, D.
    Sloan, K.
    Mohamed, B.
    Bohnsack, M.
    Hasenfuss, G.
    Fischer, A.
    Toischer, K.
    EUROPEAN HEART JOURNAL, 2018, 39 : 644 - 645